GSK is the latest to turn its back on prominent industry lobbying group Biotechnology Innovation Organization (BIO), ...

The split is no surprise: it has been public knowledge since the end of 2018 that GSK is going to spin off its consumer health business into a joint venture with Pfizer, but this is the first time ...

GlaxoSmithKline’s chairman, Philip Hampton, may be considering splitting the company amid pressure from top investors to separate the company into consumer, pharma and vaccines divisions.

GSK to pay $70 million to settle whistleblower lawsuit Pfizer and Sanofi also settling Zantac cases Boehringer Ingelheim faces trial, denies wrongdoing Oct 9 (Reuters) - GSK (GSK.L), opens new tab ...

Several companies such as Shriram Finance, Symphony, etc. will be in focus today on account of corporate actions.

GSK's major growth drivers, Shingrix and Arexvy, along with recent legal progress, make its current undervaluation ...

Today, Benzinga's options scanner spotted 8 options trades for GSK. This isn't normal. The overall sentiment of these big-money traders is split between 25% bullish and 50%, bearish. Out of all of ...

The Moderna lawsuits echo similar claims made by GSK when it sued Pfizer and BioNTech for allegedly infringing upon the company’s mRNA patents back in April. At the time, Pfizer voiced ...